Our pipeline starts with strong science; aimed at translating immunology breakthroughs into differentiated medicines.
argenx engineers first-in-class therapies for rare diseases – where underserved patients need breakthroughs and the healthcare community needs options.
Our franchise-focused approach to development has created a pipeline that is as broad as it is deep, allowing us to advance select opportunities ourselves while partnering others.
Pipeline
![Vyvgart](/sites/default/files/program-logo/program_logos_vyvgart.png)
![](/sites/default/files/styles/program_logo/public/clinical-trial-logo/ct_adaptjr_pl.png?itok=LMoiPP-P)
![](/sites/default/files/disease-phase-title-logo/partner_logos_Japan_0.png)
- Primary ITP is a rare, often chronic disorder where IgG antibodies cause reduced numbers of platelets leading to an increased risk of bleeding and bruising
- IV efgartigimod and SC efgartigimod
Pipeline
![Vyvgart Hytrulo](/sites/default/files/program-logo/program_logos_vyvgart_Hytrulo.png)
![Adapt SC](/sites/default/files/styles/program_logo/public/clinical-trial-logo/argenx_adaptSC_newlogo.png?itok=waC5snSG)
- CIDP is a rare, chronic disorder where damage to peripheral nerves, which may be caused by antibodies, results in progressive weakness and a loss of feeling in the arms and legs
- SC efgartigimod
![adhere](/sites/default/files/styles/program_logo/public/clinical-trial-logo/argenx_adhere_newlogo.png?itok=WGiIu6bu)
![Us flag](/sites/default/files/disease-phase-title-logo/USflag_icon.png)
- Primary ITP is a rare, often chronic disorder where IgG antibodies cause reduced numbers of platelets leading to an increased risk of bleeding and bruising
- IV efgartigimod and SC efgartigimod
![Adapt Seron](/sites/default/files/styles/program_logo/public/clinical-trial-logo/adaptseron_ct.png?itok=z7lbd0wH)
![](/sites/default/files/styles/program_logo/public/clinical-trial-logo/ct_uplighted_pl.png?itok=GLrYYmn3)
![](/sites/default/files/styles/program_logo/public/clinical-trial-logo/ballad_logo.png?itok=qa-FkuU4)
![](/sites/default/files/styles/program_logo/public/clinical-trial-logo/alkivia_logo.png?itok=tmUnSfeq)
![](/sites/default/files/disease-phase-title-logo/partner_logos_IQVIA.png)
![Rho study](/sites/default/files/styles/program_logo/public/clinical-trial-logo/argenx_rhostudy_newlogo.png?itok=oXiACkMW)
![](/sites/default/files/disease-phase-title-logo/partner_logos_zailab_0.png)
![](/sites/default/files/disease-phase-title-logo/partner_logos_zailab_1.png)
- ARGX-117 is designed to block complement activity with potential to reduce tissue inflammation and the adaptive immune response
- IV ARGX-117 and SC ARGX-117 (enabled with Halozyme's ENHANZE® drug delivery technology)
![](/sites/default/files/styles/program_logo/public/clinical-trial-logo/arda-immersion.png?itok=yr9ufzSL)
![](/sites/default/files/styles/program_logo/public/clinical-trial-logo/ct_varvara_pl.png?itok=9qE1tEgc)
- CIDP is a rare, chronic disorder where damage to peripheral nerves, which may be caused by antibodies, results in progressive weakness and a loss of feeling in the arms and legs
- SC efgartigimod
Pipeline
ARGX-119
Preclinical pipeline candidates
ARGX-109
ARGX-121
ARGX-213
ARGX-220
Externally Sponsored Research
We believe in accelerating discovery processes to bring solutions to patients through innovative and collaborative science-driven research.
Externally Sponsored Research (ESR) can lead to meaningful advances in disease understanding and treatment.
![Externally Sponsored Research](/sites/default/files/paragraph-image/ESR_img_1.jpeg)
Partnered Programs
argenx has several assets that emerged from the Immunology Innovation Program that have been out-licensed to a partner for further development.
Pipeline
![Leo pharma logo](/sites/default/files/styles/program_logo/public/program-images/leo-pharma-logo.png?itok=9S9YH0Bw)
LP0145 (ARGX-112) was designed as a SIMPLE Antibody® to block receptor, IL22R. LEO Pharma is evaluating the antibody for atopic dermatitis.
![Leo pharma logo](/sites/default/files/styles/program_logo/public/program-images/leo-pharma-logo.png?itok=9S9YH0Bw)
Pipeline
![Agomab logo](/sites/default/files/styles/program_logo/public/program-images/agomab-logo.png?itok=jFW1m9HQ)
AgomAb Therapeutics, a privately held, venture-backed company (www.agomab.com) exclusively licensed the SIMPLE Antibody® technology to generate a set of HGF-mimetic agonists directed at the MET receptor. The lead antibody, AGMB-101 (previously referred to as ARGX-114), has the potential to regenerate damaged tissue in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
![Agomab logo](/sites/default/files/styles/program_logo/public/program-images/agomab-logo.png?itok=jFW1m9HQ)
Pipeline
![abbvie logo](/sites/default/files/styles/program_logo/public/program-images/abbvie-logo.png?itok=y-gZ29uC)
ARGX-115, now known as ABBV-151, was designed as a SIMPLE Antibody® inhibitor of GARP-TGF-β1 and is being investigated by AbbVie for the treatment of cancer. ARGX-115 is designed to block GARP and to reactive the immune system against tumors.
![abbvie logo](/sites/default/files/styles/program_logo/public/program-images/abbvie-logo.png?itok=y-gZ29uC)